232 related articles for article (PubMed ID: 21669373)
21. Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Wu B; Tobe RG; Liu Y; He B
Clin Drug Investig; 2018 Jul; 38(7):621-630. PubMed ID: 29713921
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Kim JH; Tan DS; Chan MYY
Pharmacogenomics J; 2021 Apr; 21(2):243-250. PubMed ID: 33462345
[TBL] [Abstract][Full Text] [Related]
25. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
26. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
27. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
28. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D
Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078
[TBL] [Abstract][Full Text] [Related]
29. [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Molina-Cuadrado E; Mateo-Carrasco H; Nieto-Guindo P; Rodríguez-Gómez P
Farm Hosp; 2014 Jul; 38(4):266-75. PubMed ID: 25137159
[TBL] [Abstract][Full Text] [Related]
30. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
31. Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
De la Puente C; Vallejos C; Bustos L; Zaror C; Velasquez M; Lanas F
J Clin Epidemiol; 2017 Jun; 86():117-124. PubMed ID: 27989953
[TBL] [Abstract][Full Text] [Related]
32. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Jiang M; You JH
Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
[TBL] [Abstract][Full Text] [Related]
33. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome.
van den Broek WWA; van Paassen JG; Gimbel ME; Deneer VHM; Ten Berg JM; Vreman RA
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):76-84. PubMed ID: 35723240
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Thi Thu Nguyen T; Van Do D; Mellstrom C; Quang Nguyen T; Manh Pham H; Van Hoang S; Cong Luu T; Le Phuong T
Adv Ther; 2021 Jul; 38(7):4026-4039. PubMed ID: 34115329
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Sorich MJ; Horowitz JD; Sorich W; Wiese MD; Pekarsky B; Karnon JD
Pharmacogenomics; 2013 Dec; 14(16):2013-21. PubMed ID: 24279856
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes.
Gouveia M; Borges M; Trindade R; Rikner K
Rev Port Cardiol; 2015 Jan; 34(1):17-25. PubMed ID: 25528973
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada.
Grima DT; Brown ST; Kamboj L; Bainey KR; Goeree R; Oh P; Ramanathan K; Goodman SG
Clinicoecon Outcomes Res; 2014; 6():49-62. PubMed ID: 24493930
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Narasimhalu K; Ang YK; Tan DSY; De Silva DA; Tan KB
Clin Drug Investig; 2020 Nov; 40(11):1063-1070. PubMed ID: 32959334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]